Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1955 2
1957 1
1959 1
1960 5
1961 6
1962 3
1964 1
1965 7
1966 18
1967 23
1968 23
1969 24
1970 28
1971 27
1972 33
1973 36
1974 33
1975 37
1976 34
1977 40
1978 49
1979 49
1980 49
1981 46
1982 62
1983 68
1984 61
1985 53
1986 78
1987 60
1988 60
1989 86
1990 91
1991 95
1992 102
1993 106
1994 147
1995 136
1996 161
1997 161
1998 161
1999 172
2000 171
2001 197
2002 178
2003 217
2004 201
2005 232
2006 236
2007 286
2008 282
2009 320
2010 326
2011 346
2012 385
2013 406
2014 447
2015 389
2016 346
2017 359
2018 334
2019 368
2020 336
2021 362
2022 308
2023 244
2024 107

Text availability

Article attribute

Article type

Publication date

Search Results

9,067 results

Results by year

Filters applied: . Clear all
Page 1
Tebentafusp: First Approval.
Dhillon S. Dhillon S. Drugs. 2022 Apr;82(6):703-710. doi: 10.1007/s40265-022-01704-4. Drugs. 2022. PMID: 35364798 Review.
Restoring tumor immunogenicity with dendritic cell reprogramming.
Zimmermannova O, Ferreira AG, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, Met Ö, Caiado I, Shapiro IE, Michaux J, Humbert M, Soto-Cabrera D, Benonisson H, Silvério-Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, Höglund M, Miharada K, Nakamura Y, Hugues S, Greiff L, Lindstedt M, Rosa FF, Pires CF, Bassani-Sternberg M, Svane IM, Pereira CF. Zimmermannova O, et al. Sci Immunol. 2023 Jul 14;8(85):eadd4817. doi: 10.1126/sciimmunol.add4817. Epub 2023 Jul 7. Sci Immunol. 2023. PMID: 37418548 Free PMC article.
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.
Ho P, Melms JC, Rogava M, Frangieh CJ, Poźniak J, Shah SB, Walsh Z, Kyrysyuk O, Amin AD, Caprio L, Fullerton BT, Soni RK, Ager CR, Biermann J, Wang Y, Khosravi-Maharlooei M, Zanetti G, Mu M, Fatima H, Moore EK, Vasan N, Bakhoum SF, Reiner SL, Bernatchez C, Sykes M, Mace EM, Wucherpfennig KW, Schadendorf D, Bechter O, Shah P, Schwartz GK, Marine JC, Izar B. Ho P, et al. Cancer Cell. 2023 Jul 10;41(7):1207-1221.e12. doi: 10.1016/j.ccell.2023.05.014. Epub 2023 Jun 15. Cancer Cell. 2023. PMID: 37327789
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion.
Leuzzi G, Vasciaveo A, Taglialatela A, Chen X, Firestone TM, Hickman AR, Mao W, Thakar T, Vaitsiankova A, Huang JW, Cuella-Martin R, Hayward SB, Kesner JS, Ghasemzadeh A, Nambiar TS, Ho P, Rialdi A, Hebrard M, Li Y, Gao J, Gopinath S, Adeleke OA, Venters BJ, Drake CG, Baer R, Izar B, Guccione E, Keogh MC, Guerois R, Sun L, Lu C, Califano A, Ciccia A. Leuzzi G, et al. Cell. 2024 Feb 15;187(4):861-881.e32. doi: 10.1016/j.cell.2024.01.008. Epub 2024 Jan 31. Cell. 2024. PMID: 38301646
CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma.
Houles T, Lavoie G, Nourreddine S, Cheung W, Vaillancourt-Jean É, Guérin CM, Bouttier M, Grondin B, Lin S, Saba-El-Leil MK, Angers S, Meloche S, Roux PP. Houles T, et al. Nat Commun. 2022 Oct 29;13(1):6457. doi: 10.1038/s41467-022-34179-8. Nat Commun. 2022. PMID: 36309522 Free PMC article.
High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.
Mizuno S, Ikegami M, Koyama T, Sunami K, Ogata D, Kage H, Yanagaki M, Ikeuchi H, Ueno T, Tanikawa M, Oda K, Osuga Y, Mano H, Kohsaka S. Mizuno S, et al. Mol Cancer Ther. 2023 Feb 1;22(2):227-239. doi: 10.1158/1535-7163.MCT-22-0302. Mol Cancer Ther. 2023. PMID: 36442478 Free PMC article.
MCU controls melanoma progression through a redox-controlled phenotype switch.
Stejerean-Todoran I, Zimmermann K, Gibhardt CS, Vultur A, Ickes C, Shannan B, Bonilla Del Rio Z, Wölling A, Cappello S, Sung HM, Shumanska M, Zhang X, Nanadikar M, Latif MU, Wittek A, Lange F, Waters A, Brafford P, Wilting J, Urlaub H, Katschinski DM, Rehling P, Lenz C, Jakobs S, Ellenrieder V, Roesch A, Schön MP, Herlyn M, Stanisz H, Bogeski I. Stejerean-Todoran I, et al. EMBO Rep. 2022 Nov 7;23(11):e54746. doi: 10.15252/embr.202254746. Epub 2022 Sep 26. EMBO Rep. 2022. PMID: 36156348 Free PMC article.
9,067 results